

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.

[Get News Alerts by Email](#)

All Years

Search

Go

[Advanced Search](#)

Apr 18 2024

[BioLife Solutions Announces the Divestiture of its Stirling Freezer Business](#)

BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader...

Mar 04 2024

[BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Feb 29 2024

[BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results](#)

Fourth quarter Cell Processing revenue up 11% sequentially to \$14.8 million, and positive adjusted EBITDA of \$700,000 Expects 2024 revenue of \$95.5 - \$100.0 million excluding freezer business and...

Feb 20 2024

[BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Jan 08 2024

[BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue](#)

Fourth quarter Cell Processing revenue increased 11% sequentially to \$14.8 million BOTHELL, Wash., Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"),...

Nov 09 2023

[BioLife Solutions Reports Third Quarter 2023 Financial Results](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene...

Nov 02 2023

[BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Oct 19 2023

[BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023](#)

Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of \$33.3...

Aug 08 2023

[BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business](#)

Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2023 /PRNewswire/ -- BioLife...

Jul 27 2023

[BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Jun 14 2023

[Jun 01 2023](#)

[BioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

[Jun 06 2023](#)

[BioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen \(LN2\) Controlled-Rate Freezer](#)

Large-Capacity Tabletop Freezer Expands Line of Controlled-Rate Freezers for Cell and Gene Therapies; Now Available for Order BOTHELL, Wash., June 6, 2023 /PRNewswire/ -- BioLife Solutions, Inc....

[May 10 2023](#)

[BioLife Solutions Reports First Quarter 2023 Financial Results](#)

Revenue of \$37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022...

[May 02 2023](#)

[BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

[Mar 16 2023](#)

[BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results](#)

Record full year revenue of \$161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and...

[Mar 10 2023](#)

[BioLife Solutions Reports Immaterial Financial Exposure to Silicon Valley Bank](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided...

[Mar 09 2023](#)

[BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023](#)

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools

and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Mar 01 2023

[BioLife Solutions Launches Ultraguard™ -70°C Phase Change Material \(PCM\) Accessory to Provide Backup Cooling in ULT Freezers and Dry Ice Alternative for Benchtop Biologic Material Storage](#)

Exclusive global supplier of non-toxic, non-flammable PCM; first to operate at -70°C, meeting critical temperature requirement of biologic materials. BOTHELL, Wash., March 1, 2023 /PRNewswire/ --...

Jan 17 2023

[BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and...

Jan 10 2023

[BioLife Solutions Named One of Seattle Business Magazine's Washington's Best Companies to Work For](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and...

Jan 09 2023

[BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance](#)

Record quarterly revenue of \$44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of \$161.9 million up 36% over 2021, with organic revenue...

Dec 19 2022

[BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023](#)

Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue...

Nov 21 2022

[BioLife Solutions Expands Intellectual Property Estate](#)

7 New Granted Patents; 43 Submitted Patent Applications Global Portfolio Now Totals 148 Issued and 114 Pending Patents BOTHELL, Wash., Nov. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc....

Nov 17 2022

[BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report](#)

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and...

Nov 09 2022

[BioLife Solutions Reports Third Quarter 2022 Financial Results](#)

Record revenue of \$40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier
Cash flow...

Show per page

«	1	2	3	4	5	6	7	8	9	...	16	»
---	---	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	-----	--------------------	---



<https://investors.biolifesolutions.com/press-releases?l=25>